The Quality Lowdown: Rewarding Your Best Quality Critics
Executive Summary
Lupin hires former nemesis at FDA, how Baker exposed Hisun’s ‘full investigation,’ Cetylite’s many methods for overcoming OOS results, old school inspection-driven recalls at Vitae Enim Vitae Scientific and a critique of Catalent filling line’s non-deliberate response to the pandemic.
You may also be interested in...
Warning Letters Special Report: Where Investigations By Prescription Drug Product Firms Fell Short
Warning letters examined in part five of our in-depth report showed how prescription drug firms got into trouble with the US FDA in 2022 by conducting investigations that were too narrow and that failed to trigger appropriate corrective actions. Several firms failed in their sterile injectables contamination investigations. Other inquiries failed to establish proper control of tablet and capsule manufacturing.
The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?
As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.
Return Of Ductwork Cross-Contamination In Plants Flagged By US FDA Experts
Cleaning oversights are again allowing drug residues to collect in manufacturing equipment ductwork and contaminate drug product batches at sometimes dangerous levels, agency enforcement and compliance officials say. They share some ideas for getting such problems under control.